Endocrine Abstracts

Objectives: To describe the prevalence of liver steatosis in a cohort of patients with Cushing’s disease.Methods: Cross-sectional descriptive study. We included 59 patients with Cushing’s disease from our cohort of patients who underwent a Fibroscan to analyze the degree of hepatic steatosis (CAP measured in dB/m) and liver fibrosis (fibrosis measured in kPa). Biochemical algorithms of liver steatosis and fibrosis were assessed.<p class="ab...

Introduction: The prevalence and comorbidities of NAFLD in CD are unknown. There is only one study wich set the prevalence of NAFLD by CT images in 20%1.Objectives: Describe the prevalence of NAFLD and fibrosis in CD and analize predictive biomarkers of NAFLDMethods: Transversal descriptive study. 31 patients with CD; 11 active, 20 cured. Women 24 (77%), men 7 (23%). 54 years mean age. NAFLD was valorated by Hepatic Stea...

Craniopharyngiomas (CP) are low-prevalent tumors characterized for their local invasiveness and poor clinical outcomes, often requiring aggressive therapeutic measures. Ki67 is a marker of proliferation with good correlation with tumor recurrence in many solid tumors but this relationship is unclear in CP. Our aim is to determine whether Ki67 could be a marker for recurrence in CP.Material and methods: Descriptive retrospective observational study. All p...

Pituitary neuroendocrine tumors (PitNETs) constitute approximately 15% of all intracranial tumors and comprise a varied type of neoplasms that, despite being rarely metastatic, can cause severe comorbidities and increased mortality related to the mass effects and hormonal hypersecretion. The high expression levels of somatostatin and dopamine receptors in these tumors has led to the use of somatostatin analogues (SSAs) and dopamine agonists (DAs) as pharmacological treatments....

IntroductionCushing’s disease is the result of prolonged exposure to excess cortisol caused by a pituitary tumor, known as corticotropinoma, which hypersecretes adrenocorticotropin (ACTH). Treatment with somatostatin analogs (SSA) has been shown to reduce hormone secretion and, to a lower extent, tumor growth in some subtypes of pituitary tumors, such as growth hormone secreting tumors. However, SSA are commonly ineffective in corticotropinomas. Pre...

Background: Cushing’s disease is the result of prolonged and excessive exposure to cortisol caused by a pituitary tumor. Treatment with somatostatin analogs (SSA), which can reduce hormone secretion and tumor growth in other pituitary tumors (e.g., somatotropinomas), is usually ineffective in corticotropinomas. Previous studies indicated that presence of the truncated SST5TMD4 receptor variant is associated with a lack of response to SSA in acromegaly; but, its presence a...